弥漫性大B细胞淋巴瘤
医学
淋巴瘤
内科学
滤泡性淋巴瘤
病态的
B症状
胃肠病学
边缘地带
总体生存率
单变量分析
病理
肿瘤科
B细胞
多元分析
免疫学
抗体
作者
Cai Sun,Ziyuan Shen,BIAN Zhenzhen,Yuanyuan Ma,Jiaqin Li,Yuhan Ma,Xuguang Song,Dongmei Yan,Hui Liu,Zhenyu Li,Wei Sang,Kailin Xu
出处
期刊:Clinical Laboratory
[Clinical Laboratory Publications]
日期:2022-01-01
卷期号:68 (07/2022)
被引量:1
标识
DOI:10.7754/clin.lab.2021.211028
摘要
A variety of indolent lymphomas, particularly marginal zone lymphoma (MZL) and follicular lymphoma (FL) can be histologically transformed to diffuse large B-cell lymphoma (DLBCL). Little is known about the disparity of clinicopathologic characteristics between transformed DLBCL (tDLBCL) and primary DLBCL (pDLBCL).This retrospective study analyzed the clinicopathological hallmarks of 10 tDLBCL (7 MZL and 3 FL) and 40 pDLBCL from the Affiliated Hospital of Xuzhou Medical University.Patients of tDLBCL had a higher ECOG score, more B-symptoms, and lower serum albumin level than those in pDLBCL (60.0% vs. 7.50%, 40.0% vs. 10.0%, and 90.0% vs. 10.0%, respectively, p < 0.01). Pathologically, tDLBCL had more c-Myc and BCL-2 dual-expression than that in pDLBCL (60.0% vs. 25.0%, p < 0.01). The positive rate of CD5 expression and the proportion of high Ki-67 score in tDLBCL were higher than those in pDLBCL (50.0% vs. 7.5%, 50.0% vs. 32.5%, respectively, p < 0.01). The median overall survival and progression-free survival were 14 months and 11 months in tDLBCL, 35 months and 28 months in pDLBCL (p < 0.05 and p < 0.001).Our results demonstrate that tDLBCL manifested aggressive clinical course and pathological features of Myc/BCL-2 expression, CD5 expression, and high Ki-67 score.
科研通智能强力驱动
Strongly Powered by AbleSci AI